Comparing Tribbles Homolog 3 (TRIB3) Protein Expression Levels with Clinicopathological Characteristics and Survival Among Neuroblastoma Patients.
Neuroblastoma
TRIB3
biomarker
prognosis
survival
Journal
Clinical Medicine Insights. Oncology
ISSN: 1179-5549
Titre abrégé: Clin Med Insights Oncol
Pays: United States
ID NLM: 101525771
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
04
2023
accepted:
10
08
2023
medline:
25
9
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
epublish
Résumé
Tribbles Homolog 3 (TRIB3) is a member of the pseudokinase family of tribbles and acts as an adaptor protein to regulate different cellular processes. Upregulation of TRIB3 expression was shown either as a favorable or an adverse prognostic factor in various adult malignancies. However, TRIB3 expression has not been examined in pediatric cancers. Neuroblastoma is the most common malignant solid tumor of childhood, which affects mostly children under 5 years old. Risk stratification of patients defined by International Neuroblastoma Risk Group was used to determine prognosis and treatment of the disease. This study aimed to examine the relationship between TRIB3 protein expression levels and clinicopathological features and survival of patients. TRIB3 protein expression was analyzed using immunohistochemical staining on formalin-fixed paraffin-embedded tissue samples of neuroblastoma patients (n = 56). Survival analyses were performed with Kaplan-Meier method and log-rank tests. Association between TRIB3 expression and clinicopathological characteristics were analyzed with Spearman's correlation. Of the patients, 32.1% were in the low-risk group, 21.4% in the medium-risk group, and 46.4% in the high-risk group. Survival analysis was performed in the entire neuroblastoma patient group and sub-risk groups of neuroblastoma patients. In the entire patient group, there was no significant difference in overall survival ( TRIB3 expression is a potential predictive biomarker for low-risk neuroblastoma patients.
Sections du résumé
Background
UNASSIGNED
Tribbles Homolog 3 (TRIB3) is a member of the pseudokinase family of tribbles and acts as an adaptor protein to regulate different cellular processes. Upregulation of TRIB3 expression was shown either as a favorable or an adverse prognostic factor in various adult malignancies. However, TRIB3 expression has not been examined in pediatric cancers. Neuroblastoma is the most common malignant solid tumor of childhood, which affects mostly children under 5 years old. Risk stratification of patients defined by International Neuroblastoma Risk Group was used to determine prognosis and treatment of the disease. This study aimed to examine the relationship between TRIB3 protein expression levels and clinicopathological features and survival of patients.
Methods
UNASSIGNED
TRIB3 protein expression was analyzed using immunohistochemical staining on formalin-fixed paraffin-embedded tissue samples of neuroblastoma patients (n = 56). Survival analyses were performed with Kaplan-Meier method and log-rank tests. Association between TRIB3 expression and clinicopathological characteristics were analyzed with Spearman's correlation.
Results
UNASSIGNED
Of the patients, 32.1% were in the low-risk group, 21.4% in the medium-risk group, and 46.4% in the high-risk group. Survival analysis was performed in the entire neuroblastoma patient group and sub-risk groups of neuroblastoma patients. In the entire patient group, there was no significant difference in overall survival (
Conclusion
UNASSIGNED
TRIB3 expression is a potential predictive biomarker for low-risk neuroblastoma patients.
Identifiants
pubmed: 37744426
doi: 10.1177/11795549231199926
pii: 10.1177_11795549231199926
pmc: PMC10515557
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11795549231199926Informations de copyright
© The Author(s) 2023.
Déclaration de conflit d'intérêts
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Med Pediatr Oncol. 2001 Jan;36(1):32-6
pubmed: 11464900
Nat Commun. 2019 Dec 16;10(1):5720
pubmed: 31844113
Int Immunopharmacol. 2023 Jan;114:109581
pubmed: 36527874
Med Res Rev. 2021 Mar;41(2):961-1021
pubmed: 33155698
Cancer Biomark. 2020;29(3):307-315
pubmed: 32716348
N Engl J Med. 2005 Nov 24;353(21):2243-53
pubmed: 16306521
Cell. 2000 May 26;101(5):523-31
pubmed: 10850494
J Clin Oncol. 2021 Oct 10;39(29):3229-3241
pubmed: 34319759
Cancers (Basel). 2021 Apr 11;13(8):
pubmed: 33920424
Children (Basel). 2018 Aug 28;5(9):
pubmed: 30154341
Cancer Lett. 2012 Apr 28;317(2):115-26
pubmed: 22123293
Jpn J Clin Oncol. 2018 Mar 1;48(3):214-241
pubmed: 29378002
Curr Opin Pediatr. 2005 Feb;17(1):7-13
pubmed: 15659956
Cell Tissue Res. 2018 May;372(2):195-209
pubmed: 29572647
J Clin Oncol. 2009 Jan 10;27(2):289-97
pubmed: 19047291
BMC Cancer. 2022 Jun 30;22(1):717
pubmed: 35768791
J Cancer Res Ther. 2017 Apr-Jun;13(2):284-290
pubmed: 28643749
Cancers (Basel). 2021 May 30;13(11):
pubmed: 34070799
Pediatr Clin North Am. 2015 Feb;62(1):225-56
pubmed: 25435121
Br J Cancer. 2009 Nov 17;101(10):1664-70
pubmed: 19904274
Science. 2003 Jun 6;300(5625):1574-7
pubmed: 12791994
J Clin Oncol. 2015 Sep 20;33(27):3008-17
pubmed: 26304901
Radiother Oncol. 2011 Oct;101(1):198-202
pubmed: 21704407
Children (Basel). 2019 Feb 11;6(2):
pubmed: 30754710
FEBS J. 2020 Oct;287(19):4170-4182
pubmed: 31621188
Curr Biol. 2000 Jun 1;10(11):623-9
pubmed: 10837248
Nat Rev Clin Oncol. 2022 Aug;19(8):515-533
pubmed: 35614230
Mol Med Rep. 2013 Jul;8(1):47-52
pubmed: 23632994
Cancers (Basel). 2022 Sep 12;14(18):
pubmed: 36139583